 Data from six abstracts to be presented, including new long-term Phase 3 results and two real-world analyses of U.S. caregiver-reported seizure and non-seizure outcomes in patients prescribed Epidiolex cannabidiol DUBLIN , Nov. 28, 2022 PRNewswire -- Jazz Pharmaceuticals plc Nasdaq: JAZZ today announced that six company-sponsored Epidiolex cannabidiol oral solution presentations, including three late-breaking abstracts, will be shared at the upcoming 2022 American Epilepsy Society AES annual meeting, which will be held December 2-6, 2022, in Nashville, TN. We understand the significant, lifelong implications of severe, childhood-onset epilepsy on both patients and their families. 